http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한용식,김명배,오광철,유상필 한국화재소방학회 2001 한국화재소방학회논문지 Vol.15 No.1
수평 평판과 충돌하는 제트에 의해 생성되는 연기유동을 관찰하기 위해 질소가스에 kerosene연기입자를 뛰워 유동장을 가시화하였다. 광원으로는 아르곤-이온 레이져 평면광이 사용되었다. Kerosene smoke의 산란 광에 의한 수직평면 상(image)과 수평평면 상을 고속 CCD 카메라와 비디오 카메라로 녹화하였으며, 얻어진 영상으로부터 연기 선단의 순간속도 및 평균속도를 측정하였다. The flow induced by a vertically impinging circular jet under a horizontal plate is investigated by visualization technique, using kerosene smoke in nitrogen gas to visualize the vortex flow and impinging flow. The light source was the sheet beam of Ar-Ion laser. The vertical and horizontal images scattering of kerosene smoke were recorded by the high speed CCD camera and the video camera. The instantaneous velocity of the smoke front were measured from the acquisited images.
Microsatellite Alterations in Serum DNA of Lung Cancer Patients
Sang Cheul Oh,Young Do Yoo,So Young Yoon,Seok Jin Kim,Jae Hong Seo,Kwang Taek Kim,Sang Won Shin,Yo Han Kim,Yeul Hong Kim,Jun Suk Kim 대한암학회 2003 Cancer Research and Treatment Vol.35 No.4
Purpose: Neoplastic progression is accompanied bymultiple genetic alterations, which include the functionalloss of tumor suppressor genes, and tumorspecific genetic alterations are increasingly being investigatedas molecular tumor markers. Recently,genetic changes including microsatellite alterationshave been found in the serum DNA of cancer patients.Many studies have shown that alterations in the DNAisolated from serum tend to be identical to thosefound in tumor tissue. If so, serum DNA alterationsmay be very useful for detecting tumoral geneticchanges. The aim of this study was to detect chromosome3p microsatellite alterations, such as loss ofheterozygosity (LOH) and m icrosatellite instability, inthe serum DNA of lung cancer patients.Methods: A total of 46 lung cancer patients wereenrolled in the study. After DNA extraction from bloodlymphocytes and the serum of lung cancer patientsusing a DNA extraction kit, microsatellite alterationswere detected by using different markers (D3S4623,D3S4597, D3S1573).Results: W e found that heterozygotes were presentin 18 of 46 cases (39%) for D3S4623, and LOH wasdetected in two of these 18 cases (11% ). In D3S4597,heterozygotes were present in 26 of 46 cases (56.5%)and LOH was detected in 9 of these 26 heterozygotes(34.6%). Heterozygotes of D3S1573 were present in 19of 46 cases (41.3%) and LOH was detected in 7 of these19 cases (36.8%). The serum DNA of 10 of 26 patientsexhibited LOH in at least one of the three markersinvestigated (38.46%).Conclusion: Our result suggest that the m icrosatellitealterations in tumor DNA can be detected in theserum of lung cancer patients, and that serum DNAmay be usefully used for the diagnosis and screeningof lung cancer. (Cancer Res Treat. 2003;35:289-293)
Update of Adjuvant Chemotherapy for Resected Gastric Cancer
Oh, Sang-Cheul The Korean Gastric Cancer Association 2012 Journal of gastric cancer Vol.12 No.1
Gastric cancer is the second cause of cancer that is related to death and the fourth most common cancer, worldwide. Complete resection of cancer is the only curative treatment for gastric cancer. However, even if complete resection is possible, recurrence is frequently observed in Gastric patients. Therefore, adjuvant treatment modality for resectable gastric cancer is needed to increase the survival of patients. This study wants to describe the role of adjuvant chemotherapy for resectable gastric cancer, with updated data of recent studies. Several meta-analysis studies demonstrated a benefit of adjuvant chemotherapy for resectable gastric cancer. Due to the heterogeneity of the population and regimens, there is no consensus regarding the adjuvant chemotherapy. Recently published, well designed phase III studies demonstrated the statistically significance of adjuvant chemotherapy for the resectable gastric cancer, with the extended lymph node dissection. Further phase III trials, to determine the best regimen and schedule of adjuvant chemotherapy, was suggested to use the fluoropyrimidine based regimen as control group.
( Eun Sang Yu ),( In Keun Choi ),( Kyong Hwa Park ),( Sang Cheul Oh ),( Jae Hong Seo ),( Sang Won Shin ),( Yeul Hong Kim ),( Jun Suk Kim ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: Docetaxel has proven its efficacy in the treatment of advanced gastric cancer. Weekly chemotherapy is well-tolerated in patients with poor performance status (PS). Therefore, we analyzed the results of weekly docetaxel mono chemotherapy after progression with previous treatment in advanced gastric cancer patients with poor PS. Methods: We performed a retrospective analysis involving 32 patients with advanced gastric cancer who had weekly docetaxel treatment as above 2nd line chemotherapy. Results: Patients with PS more than ECOG 2 were about 90% (29/32). The median survival of patients who were treated by weekly docetaxel as 2nd line therapy was 209 days (95% CI 178-240 days). There was no complete and partial response. The disease control rate including stable disease was 34.4% (11/32). Median survival for all patients was 114 days (95% CI 71-156 days). Patients who were treated by weekly docetaxel as 2nd or 3rd line chemotherapy had a median survival time of 189 days (95% CI, 151-227 days) which was significantly longer than that were treated as above 4th line chemotherapy (median 189 days vs. 98 days; P<0.01, log-rank test). Seven patients took 4-week schedule (4-wk), 25 patients received modified 3-week treatment (3-wk) of docetaxel due to toxicity. In subgroup analysis, there was a tendency of longer progression free survival (PFS) in patients with 3-wk than 4-wk (PFS:75 days in 3-wk vs. 47 days in 4-wk, P=0.06). As 2nd line chemotherapy, 3-wk showed signifi-cant longer PFS than 4-wk in weekly docetaxel chemotherapy (p=0.037). Toxicity was tolerable. Conclusions: Weekly docetaxel chemotherapy as 2nd line treatment showed overall survival which is comparable to other 2nd line chemotherapy in patients with advanced gastric cancer. Modified 3-week treatment might be better than 4-week docetaxel schedule as 2nd line chemotherapy in patients with poor PS.